Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

90.95 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Law Offices of Frank R. Cruz Encourages Merck & Co (MRK) Investors to Inquire About Securities Fraud Class Action
From Law Offices of Frank R. Cruz
Via Business Wire
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & Co., Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Is Merck Stock a Buy?
Via The Motley Fool
Looking Into Merck & Co's Recent Short Interest
 
Via Benzinga
Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock
 
Via Benzinga
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
3 Magnificent S&P 500 Dividend Stocks Down 36% to 64% to Buy and Hold Forever
The majority of the market isn't seeing the bigger picture for these stocks and their underlying companies. Big mistake. 
Via The Motley Fool
Topics Stocks
Why NYSE:MRK is a Top Pick for Dividend Investors.
Why MERCK & CO. INC. (NYSE:MRK) provides a good dividend, while having solid fundamentals. 
Via Chartmill
Merck to Participate in the TD Cowen 45th Annual Health Care Conference
From Merck & Co., Inc.
Via Business Wire
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Via The Motley Fool
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
Law Offices of Howard G. Smith Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
2 Healthcare Stocks with Big Upside and 1 to Skip
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management. 
Via Stocktwits
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Merck & Co (MRK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Buybacks Galore: 3 Mega-Caps Just Approved Billions in Buybacks
Check out these three mega-cap names, valued over $200 billion each, that just authorized a combined $28 billion in buybacks. 
Via MarketBeat
Topics Earnings Economy Intellectual Property
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment. 
Via Stocktwits
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors. 
Via Benzinga
Topics ETFs Government World Trade
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK
From Robbins LLP
Via GlobeNewswire
Europe Approves Merck's Cancer Drug For Two Indications
Merck's Welireg receives conditional EU approval for VHL disease-associated tumors and advanced RCC, expanding its global presence across 30+ countries. 
Via Benzinga
This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.